| 药品名称 | 药品通用名称：注射用 A 型肉毒毒素 | | | --- | --- | --- | | | 英文名/拉丁名：Botulinum Toxin Type A for Injection | | | 生产企业 | BioPharma Co., Ltd. | Huons | | 申请事项 | 药品注册(境外生产) | | | 剂型 | | 注射剂 | | 规格 | U/瓶 | 100 | | 注册分类 | 治疗用生物制品 | | | 处方药/非处方药 | | 处方药 | | 药品批准文号 | SJ20260001 | 国药准字 | | 药品批准文号有效期 | 年 月 日 2031 01 04 | 至 | | 证书编号 | 2026S00059 | | | 上市许可持有人 | BioPharma Co., Ltd. | Huons | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规定，经 | | | | 审查，本品符合药品注册的有关要求，批准注册，发 | | | | 给药品注册证书。 | | 一、药品注册证书的基本情况 二、药品的其他相关情况 证券代码：300896 证券简称：爱美客 公 ...

Group 1 - The company, Aimeike (300896.SZ), currently has no business layout related to brain-computer interfaces [1]

Core Viewpoint - The stock of Aimeike has shown a mixed performance with a recent increase in price, but the company has reported a significant decline in revenue and net profit for the year 2025. Group 1: Stock Performance - On January 8, Aimeike's stock rose by 2.00%, reaching 148.25 yuan per share, with a trading volume of 315 million yuan and a turnover rate of 1.03%, resulting in a total market capitalization of 44.859 billion yuan [1] - Year-to-date, Aimeike's stock price has increased by 4.61%, with a 4.96% rise over the last five trading days, a 5.01% increase over the last 20 days, but a decline of 15.52% over the last 60 days [1] Group 2: Financial Performance - For the period from January to September 2025, Aimeike reported an operating revenue of 1.865 billion yuan, a year-on-year decrease of 21.49%, and a net profit attributable to shareholders of 1.093 billion yuan, down 31.05% year-on-year [2] - Since its A-share listing, Aimeike has distributed a total of 3.887 billion yuan in dividends, with 3.012 billion yuan distributed over the past three years [3] Group 3: Shareholder Information - As of December 31, Aimeike had 60,100 shareholders, a decrease of 2.71% from the previous period, with an average of 3,472 circulating shares per person, an increase of 2.78% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, holding 6.8295 million shares (a decrease of 151,300 shares), and Huabao CSI Medical ETF, holding 4.2589 million shares (a decrease of 802,100 shares) [3]

Group 1 - The Shanghai Composite Index rose by 0.05% on January 7, with 17 industries experiencing gains, led by the comprehensive and coal sectors, which increased by 3.86% and 2.47% respectively [1] - The oil and petrochemical and non-bank financial sectors saw the largest declines, with decreases of 1.73% and 1.13% respectively [1] - The beauty and personal care industry ranked third in terms of decline for the day, falling by 1.03% [2] Group 2 - The beauty and personal care industry experienced a net outflow of 73.58 million yuan, with 29 stocks in the sector, of which only 4 rose while 24 fell [2] - The top three stocks with the largest net outflows in the beauty and personal care sector were Qingdao Kingking, Aimeike, and Furida, with outflows of 43.47 million yuan, 21.05 million yuan, and 15.05 million yuan respectively [2][3] - The stock with the highest net inflow was Shuiyang Co., with an inflow of 18.80 million yuan, followed by Perleya and Zhongshun Jierou with inflows of 10.12 million yuan and 9.53 million yuan respectively [2][3]

证券之星消息，1月7日医疗美容板块较上一交易日下跌0.74%，*ST美谷领跌。当日上证指数报收于 4085.77，上涨0.05%。深证成指报收于14030.56，上涨0.06%。医疗美容板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗美容板块主力资金净流出2679.3万元，游资资金净流入1374.35万元，散户 资金净流入1304.95万元。医疗美容板块个股资金流向见下表： | 代码 | 名称 | 主力净流入 (元) | | | | 主力净占比 游资净流入 (元) 游资净占比 散户净流入 (元) 散户净占比 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 920982 锦波生物 | | | 2755.02万 | 12.55% | -1248.51万 | -5.69% | -439.98万 | -2.00% | | 688363 华熙生物 | | | 204.38万 | 1.30% | 771.92万 | 4. ...

证券之星消息，1月6日医疗美容板块较上一交易日上涨0.66%，爱美客领涨。当日上证指数报收于 4083.67，上涨1.5%。深证成指报收于14022.55，上涨1.4%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 146.49 | 1.06% | 3.41万 | 4.98 乙 | | 688363 | 华熙生物 | 44.91 | 0.34% | 5.16万 | 2.31亿 | | 920982 | 锦波生物 | 236.12 | -0.22% | 7324.94 | 1.74亿 | | 000615 | *ST美谷 | 3.46 | -0.86% | 13.90万 | 4782.12万 | 从资金流向上来看，当日医疗美容板块主力资金净流出1283.62万元，游资资金净流入772.62万元，散户 资金净流入511.0万元。医疗美容板块个股资金流向见下表： | 代码 | 名称 | 主力净流入 (元) | | | 主力净占比 游资净流入 ...

Group 1 - The medical ETF (512170) opened high on January 6, rising over 1% and reaching a 20-day high, with real-time transaction volume exceeding 350 million yuan. The ETF recorded a daily increase of over 5%, marking five consecutive days of gains [1][5] - Brain-computer interface stocks, including Sanbo Brain Science and Meihua Medical, both hit the 20% daily limit up, achieving two consecutive boards. Conversely, the CXO sector saw a pullback, with Tigermed falling over 1% [1][5] Group 2 - On January 5, 2026, Elon Musk announced that Neuralink plans to start large-scale production of brain-computer interface devices, advancing the commercialization of the technology. Concurrently, the National Medical Products Administration held a meeting to expedite the review and approval of related medical devices [3][6] - According to CITIC Securities, China's brain-computer interface technology is relatively advanced globally, with potential to cultivate leading companies in the sector. This could enhance the valuations of related listed companies in the secondary market and stimulate financing in the primary market, creating a synergy between capital and industry development [7] - Zhongtai Securities noted that the pharmaceutical sector is expected to rebound in 2025 after four consecutive years of decline, driven by the realization of innovative drug export logic and industry recovery post-policy reform. Certain areas of the medical device sector may also see a reversal of difficulties [7]

证券日报网讯 1月5日，爱美客在互动平台回答投资者提问时表示，截至2025年12月31日，公司股东人 数为60075户。 （文章来源：证券日报） ...

证券之星消息，1月5日医疗美容板块较上一交易日上涨2.22%，华熙生物领涨。当日上证指数报收于 4023.42，上涨1.38%。深证成指报收于13828.63，上涨2.24%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688363 | 华熙生物 | 44.76 | 2.47% | 4.79万 | 2.14亿 | | 300896 | 爱美客 | 144.95 | 2.28% | 3.97万 | 5.72亿 | | 920982 | 锦波生物 | 236.64 | 1.26% | 7690.59 | 1.80 Z | | 000615 | *ST美谷 | 3.49 | 0.00% | 11.32万 | 3982.21万 | 从资金流向上来看，当日医疗美容板块主力资金净流入1362.9万元，游资资金净流出704.42万元，散户资 金净流出658.47万元。医疗美容板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345 ...

Group 1: Market Performance - The medical device ETF fund (159797) surged over 5% after four consecutive days of decline, indicating a significant rebound in the market [1] - The fund saw a net subscription of 6 million shares during the trading session, with a total inflow of over 30 million yuan in the past 10 days, including 7 days of net inflow [1] - Most component stocks of the medical device ETF fund performed positively, with notable gains including Lepu Medical reaching a 20% limit up, and other companies like United Imaging and Huatai Medical rising over 4% [1] Group 2: Neuralink and Brain-Computer Interface Developments - Neuralink is expected to enter large-scale production by January 1, 2026, with nearly automated surgical operations, enhancing safety by allowing guide wires to pass through the dura mater without opening it [4] - The advancement of Neuralink's technology is anticipated to facilitate collaboration with Tesla's Optimus humanoid robot, aiming to create a "human brain + robot" ecosystem [5] - The technology is transitioning from clinical trials to commercial viability, marking a significant step in making brain-computer interfaces widely accessible [3] Group 3: Policy and Industry Trends - The National Medical Products Administration (NMPA) emphasized the strategic importance of brain-computer interfaces in a meeting held on December 18, 2025, focusing on safety, innovation in regulatory methods, and collaboration across sectors [6] - Recent clinical trials have shown promising results for brain-computer interface systems, with successful implantations and significant improvements in patients' hand functions [6] - The rapid iteration and upgrade of brain-computer interface technology are driven by advancements in signal acquisition, materials science, and multi-modal integration, paving the way for broader applications beyond medical use [7]